Pfizer’s new lung cancer drug bags US clearance
Pfizer’s new lung cancer treatment Lorbrena has bagged US approval for previously treated patients with a specific gene mutation and metastatic disease.
Read More
Tag: ALK inhibitor
- ACD440 granted orphan drug status in the EU
- ViiV Healthcare data show lower rates of steatotic liver disease after switching to Dovato
- Tremfya data show sustained remission in ulcerative colitis through 3 years
- Brensocatib becomes first licensed treatment for non‑cystic fibrosis bronchiectasis
- Lario Therapeutics awarded $2.4m to advance calcium channel platform
